| Kimberly Lynne Bullen, | |
|
839 S Main St, London, KY 40741-1996 | |
| (606) 864-7368 | |
| Not Available |
| Full Name | Kimberly Lynne Bullen |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 839 S Main St, London, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235523606 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 017385 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Lynne Bullen, 1112 Valley Run Dr, Richmond, KY 40475-3438 Ph: (478) 335-0991 | Kimberly Lynne Bullen, 839 S Main St, London, KY 40741-1996 Ph: (606) 864-7368 |
News Archive
To examine the real impact of COVID-19 lockdown on wildlife hunting across India, a team of researchers conducted a study from March-May 2020. Using media reports and online interviews with wildlife researchers, enforcement staff and NGO employees, the research team explored the change in hunting patterns and the socio-economic and institutional factors underlying these changes.
Researchers put overdiagnosis of idiopathic intracranial hypertension (IIH) down to inaccurate ophthalmoscopic examination in headache patients and wrongly suspecting the condition in young obese women with headaches.
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability.
Research published online in The FASEB Journal shows that the improper methylation of a protein called "Septin2," which regulates the structure of cilia, was associated with an increased risk of having a neural tube defect (NTD) and confirms that cilia are important factors in determining susceptibility of NTDs.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
› Verified 1 days ago
Francis Britton Thompson, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 810 E 4th St, London, KY 40741 Phone: 606-878-7713 | |
Timothy Scott Lawson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1775 Highway 192 W, London, KY 40741 Phone: 606-877-2727 | |
Angelia Denise Hicks, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1851 Highway 192 W, London, KY 40741 Phone: 606-878-3041 Fax: 600-877-3041 | |
Dr. Brooke Feltner, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 810 E 4th St, London, KY 40741 Phone: 606-878-7713 Fax: 606-878-9458 | |
Mary N Casebolt, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 237 Parkway Hls, London, KY 40741 Phone: 606-878-1486 | |
Britney Morgan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1730 Highway 192 W, London, KY 40741 Phone: 606-878-1568 | |
Mr. Donald R Baker, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 803 Meyers Baker Rd Ste 110, London, KY 40741 Phone: 606-877-1008 Fax: 606-864-3127 |